Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval; Draft Guidance for Industry; Availability

Documents

Comments

Key Dates

Comment Period OpensJan 21, 2026

Comment Period ClosesMar 24, 2026

Type	Title	Posted	Comments	Status
Notice	Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval; Draft Guidance for Industry; Availability FR Doc: 2026-01068	Jan 21, 2026

Total Comments

2024-798

CDRH

CBER

CDER

Minimal Residual Disease and

Complete Response in Multiple Myeloma Use as

Endpoints to Support Accelerated Approval

Draft Guidance for Industry Availability